Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company
  • Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers
  • Aurora said its plan to sell is consistent with its current strategic priorities
  • Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans
  • On the market today, Cann is down 7.14 per cent, trading for 39 cents per share

Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company.

On Friday, Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers.

Aurora said its plan to sell is consistent with its current strategic priorities.

Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans.

Currently, the company is “developing a growing and diversified supply base with business to business (B2B) customers in Australia and overseas and proceeding with plans to expand its manufacturing capacity.”

In August, the company’s 2020 financial year results came out. Cann’s full-year revenue slipped 56 per cent to $1.86 million compared to the previous financial year.

With the Mildura facility expansion, Cann is expecting around $15 million in revenue for the 2021 financial year.

On the market today, Cann is down 7.14 per cent, trading for 39 cents per share at 12:31pm AEDT.

can by the numbers
More From The Market Online

‘Meaningful reduction’: Avita achieves positive Cohealyx grafting study interim results

Avita Medical has unveiled a significant reduction in mean time to skin grafting in positive interim…
London

With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment

Emyira ramps up national growth strategy with NSW recruitment campaign

Emyira has initiated a significant growth program with a targeted clinical workforce recruitment campaign underway in…

Investors will get interim results from Paradigm’s Phase III study in Q3 of this year

Paradigm Biopharma has officially passed a milestone that gives investors in the company a 'fast-track' path…